文献速递膀胱癌与上尿路尿路上皮癌

门诊光动力诊断引导激光破坏膀胱肿瘤与常规住院光动力诊断引导经尿道肿瘤电切在复发性中危低级别Ta膀胱肿瘤患者中的效果相当:一项前瞻性随机非劣效性临床试验

Outpatient Photodynamic Diagnosis-guided Laser Destruction of Bladder Tumors Is as Good as Conventional Inpatient Photodynamic Diagnosis-guided Transurethral Tumor Resection in Patients with Recurrent Intermediate-risk Low-grade Ta Bladder Tumors. A Prospective Randomized Noninferiority Clinical Trial.
PubMed 文献 · Eur Urol · 2022-09-02

这项前瞻性随机非劣效性试验在丹麦首都大区2016至2020年纳入206例组织学证实的复发性低级别Ta膀胱肿瘤患者,比较门诊局部麻醉下980nm二极管激光光凝与全麻下经尿道膀胱肿瘤电切(均以光动力诊断引导)的4个月无复发生存及治疗相关发病率。激光组4个月无复发生存较电切组高8%(95%CI -8%至24%),达到预设非劣效界值15%。

要点

  • 门诊激光光凝组4个月无复发生存较全麻电切组高8%(95%CI -8%至24%),达到预设非劣效界值15%。
  • 激光光凝期间疼痛评分(1-10分)为2.4(四分位距0.8-3.3)。
  • 电切组术后下尿路症状评分(0-100分)较激光组高13.9分(95%CI 6.9-21.0,p<0.001)。

核心结论

  • 门诊光动力诊断引导的激光光凝在去除复发性低级别Ta膀胱肿瘤方面与全麻下经尿道膀胱肿瘤电切效果相当。
  • 激光光凝组术后生活质量更好且轻微并发症频率更低。

研究设计与样本

  • 前瞻性随机非劣效性试验,随访4个月,在丹麦首都大区2016至2020年医院环境中开展。
  • 共随机206例组织学证实的复发性低级别Ta膀胱肿瘤患者,176例按方案完成治疗和随访。
  • 干预为门诊局部麻醉下980nm二极管激光膀胱肿瘤光凝,对照为全麻下经尿道膀胱肿瘤电切,两者均在光动力诊断引导下进行。

主要发现

  • 激光光凝组4个月无复发生存较电切组高8%(95%CI -8%至24%),达到预设非劣效界值15%。
  • 激光光凝期间疼痛评分(1-10分)为2.4(四分位距0.8-3.3)。
  • 电切组术后下尿路症状评分(0-100分)较激光光凝组高13.9分(95%CI 6.9-21.0,p<0.001)。
  • 电切组轻微并发症频率较激光光凝组高8.1%(95%CI 1.0-14.6%,p=0.026)。
  • 98%(95%CI 92-100%)的患者偏好激光光凝。

关键数值与推荐

  • 预设非劣效界值为15%。
  • 4个月无复发生存激光光凝组较电切组高8%(95%CI -8%至24%),达到非劣效 criterion。
  • 电切组术后下尿路症状评分较激光光凝组高13.9分(95%CI 6.9-21.0,p<0.001)。
  • 电切组轻微并发症频率较激光光凝组高8.1%(95%CI 1.0-14.6%,p=0.026)。
  • 98%(95%CI 92-100%)的患者偏好激光光凝。

临床怎么用

  • 原文结论认为门诊光动力诊断引导的激光光凝与全麻下经尿道膀胱肿瘤电切在去除复发性低级别Ta膀胱肿瘤方面效果相当,且术后生活质量更好、轻微并发症更少。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Transurethral resection of recurrent low-grade intermediate-risk Ta bladder tumor (BT) in general anesthesia (GA) is burdensome to patients and health care system. Laser technologies enable treatment in office-based settings, reducing morbidity and costs. OBJECTIVE: To compare 4-mo recurrence-free survival after outpatient department (OPD) diode laser coagulation of BT in local anesthesia and gold standard transurethral resection of BT (TUR-BT) in GA in intermediate-risk Ta low-grade BT, and to evaluate treatment-related morbidity. DESIGN, SETTING, AND PARTICIPANTS: A prospective randomized noninferiority trial with 4-mo follow-up, in the hospital setting, was conducted in Capital Region of Denmark from 2016 to 2020. Participants were patients with histologically verified Ta low-grade BT recurrence. A total of 206 patients were randomized; 176 finished treatment and follow-up as per protocol. INTERVENTION: Laser photocoagulation of bladder tumor (PC-BT) in OPD using a 980 nm diode laser compared with gold standard TUR-BT in GA, both performed with photodynamic diagnosis (PDD) guidance. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Four-month recurrence-free survival was assessed; predefined inferiority criterion was set at 15%. The secondary outcomes were pain during PC-BT, postoperative morbidity, postoperative complications, and patient's preference. RESULTS AND LIMITATIONS: Four-month recurrence-free survival was 8% higher after PC-BT (95% confidence interval [CI]: -8% to 24%). The predefined noninferiority criterion was met. Pain score (1-10) during PC-BT was 2.4 (interquartile range 0.8-3.3). Postoperative lower urinary tract symptom score (0-100) was 13.9 points higher (95% CI: 6.9-21.0, p < 0.001) in the group with transurethral resection of the bladder. The frequency of minor complications was 8.1% higher after TUR-BT (95% CI: 1.0-14.6%, p = 0.026). Of the patients, 98% (95% CI: 92-100%) preferred PC-BT. CONCLUSIONS: PDD-guided PC-BT in OPD is as good as TUR-BT in GA to remove recurrent low-grade Ta BT. Postoperative quality of life is better after PC-BT and the frequency of minor complications was lower. PATIENT SUMMARY: This study evaluates the efficacy of outpatient laser removal of low-grade noninvasive bladder tumor. Outpatient tumor removal with laser was as good as transurethral resection in general anesthesia and less burdensome to patients.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Pedersen GL, Erikson MS, Mogensen K, et al. Outpatient Photodynamic Diagnosis-guided Laser Destruction of Bladder Tumors Is as Good as Conventional Inpatient Photodynamic Diagnosis-guided Transurethral Tumor Resection in Patients with Recurrent Intermediate-risk Low-grade Ta Bladder Tumors. A Prospective Randomized Noninferiority Clinical Trial. Eur Urol. 2022. PMID: 36058804. doi:10.1016/j.eururo.2022.08.012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。